TRIM29 Antibody - #DF8050

(1)   (7)  
製品: TRIM29 Antibody
カタログ: DF8050
タンパク質の説明: Rabbit polyclonal antibody to TRIM29
アプリケーション: WB IHC IF/ICC
Cited expt.: WB, IF/ICC
反応性: Human, Mouse, Rat
予測: Pig, Bovine, Horse, Sheep, Rabbit, Dog
分子量: 66 kDa; 66kD(Calculated).
ユニプロット: Q14134
RRID: AB_2841408

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(100%), Bovine(100%), Horse(90%), Sheep(100%), Rabbit(100%), Dog(100%)
クローナリティ:
Polyclonal
特異性:
TRIM29 Antibody detects endogenous levels of total TRIM29.
RRID:
AB_2841408
引用形式: Affinity Biosciences Cat# DF8050, RRID:AB_2841408.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

Ataxia telangiectasia group D associated protein; Ataxia telangiectasia group D-associated protein; ATDC; FLJ36085; TRI29_HUMAN; TRIM 29; TRIM29; Tripartite motif containing 29; Tripartite motif containing protein 29; Tripartite motif protein 29; Tripartite motif protein TRIM29; Tripartite motif-containing protein 29;

免疫原

免疫原:

A synthesized peptide derived from human TRIM29, corresponding to a region within the internal amino acids.

Uniprot:

Q14134(TRI29_HUMAN) >>Visit HPA database.

遺伝子(ID):
TRIM29(23650)
発現特異性:
Q14134 TRI29_HUMAN:

Expressed in placenta, prostate and thymus.

タンパク質配列:
MEAADASRSNGSSPEARDARSPSGPSGSLENGTKADGKDAKTTNGHGGEAAEGKSLGSALKPGEGRSALFAGNEWRRPIIQFVESGDDKNSNYFSMDSMEGKRSPYAGLQLGAAKKPPVTFAEKGELRKSIFSESRKPTVSIMEPGETRRNSYPRADTGLFSRSKSGSEEVLCDSCIGNKQKAVKSCLVCQASFCELHLKPHLEGAAFRDHQLLEPIRDFEARKCPVHGKTMELFCQTDQTCICYLCMFQEHKNHSTVTVEEAKAEKETELSLQKEQLQLKIIEIEDEAEKWQKEKDRIKSFTTNEKAILEQNFRDLVRDLEKQKEEVRAALEQREQDAVDQVKVIMDALDERAKVLHEDKQTREQLHSISDSVLFLQEFGALMSNYSLPPPLPTYHVLLEGEGLGQSLGNFKDDLLNVCMRHVEKMCKADLSRNFIERNHMENGGDHRYVNNYTNSFGGEWSAPDTMKRYSMYLTPKGGVRTSYQPSSPGRFTKETTQKNFNNLYGTKGNYTSRVWEYSSSIQNSDNDLPVVQGSSSFSLKGYPSLMRSQSPKAQPQTWKSGKQTMLSHYRPFYVNKGNGIGSNEAP

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Horse
90
Xenopus
70
Chicken
70
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

機能:

Plays a crucial role in the regulation of macrophage activation in response to viral or bacterial infections within the respiratory tract. Mechanistically, TRIM29 interacts with IKBKG/NEMO in the lysosome where it induces its 'Lys-48' ubiquitination and subsequent degradation. In turn, the expression of type I interferons and the production of proinflammatory cytokines are inhibited. Additionally, induces the 'Lys-48' ubiquitination of STING1 in a similar way, leading to its degradation.

PTMs:

Constitutively phosphorylated by PKC on serine/threonine in A431 cells.

細胞の位置付け:

Cytoplasm. Lysosome.
Note: Colocalizes with intermediate filaments.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in placenta, prostate and thymus.

参考文献

1). HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity. Molecular Therapy, 2022 (PubMed: 36245126) [IF=12.1]

Application: WB    Species: Human    Sample: KYSE150 and KYSE510 cells

Figure 4 HCP5 stabilizes UTP3 by blocking the interaction between UTP3 and TRIM29 (A) List of UTP3-interacting E3 ligases identified using MS analysis in KYSE150 and KYSE510 cells. (B) Western blot analyses of TRIM29 and UTP3 expression in control and TRIM29-silenced (shT29#1 and shT29#2) KYSE150 and KYSE510 cells. Representative results of at least three biological replicates are shown. (C) Western blot analyses of TRIM29 and UTP3 expression in 293T cells transfected with increasing amounts of TRIM29 (0.5, 1.0, and 2.0 μg). Representative results of at least three biological replicates are shown. (D) Confocal microscopy assessment of UTP3 and TRIM29 colocalization in the indicated cells. Nuclei were stained with Hoechst 33342. Scale bars, 30 μm. (E and F) Western blot analyses of TRIM29 and UTP3 distribution after coIP assays with the indicated cells (C, cytoplasm; N, nucleus). Representative results of at least three biological replicates are shown. (G and H) Western blot analyses to assess UTP3 ubiquitination in control and TRIM29-silenced KYSE150 (G) and KYSE510 (H) cells. Representative results of at least three biological replicates are shown. (I) Western blot analyses of TRIM29 and UTP3 in coIP assays performed with control and HCP5-silenced KYSE150 and KYSE510 cells. Representative results of at least three biological replicates are shown. (J and K) Confocal microscopy assessment of PLA spots (red) in the indicated cells. Each spot indicates a single interaction between UTP3 and TRIM29 proteins. Nuclei were stained with DAPI (blue). Scale bars, 10 μm. The data are presented as the means ± SD; two-tailed t test, ∗∗∗p < 0.001, ∗∗p < 0.01; n = 3. (L) Western blot analyses to assess UTP3 ubiquitination in the indicated cells. Representative results of at least three biological replicates are shown.

Application: IF/ICC    Species: Human    Sample: KYSE150 and KYSE510 cells

Figure 4 HCP5 stabilizes UTP3 by blocking the interaction between UTP3 and TRIM29 (A) List of UTP3-interacting E3 ligases identified using MS analysis in KYSE150 and KYSE510 cells. (B) Western blot analyses of TRIM29 and UTP3 expression in control and TRIM29-silenced (shT29#1 and shT29#2) KYSE150 and KYSE510 cells. Representative results of at least three biological replicates are shown. (C) Western blot analyses of TRIM29 and UTP3 expression in 293T cells transfected with increasing amounts of TRIM29 (0.5, 1.0, and 2.0 μg). Representative results of at least three biological replicates are shown. (D) Confocal microscopy assessment of UTP3 and TRIM29 colocalization in the indicated cells. Nuclei were stained with Hoechst 33342. Scale bars, 30 μm. (E and F) Western blot analyses of TRIM29 and UTP3 distribution after coIP assays with the indicated cells (C, cytoplasm; N, nucleus). Representative results of at least three biological replicates are shown. (G and H) Western blot analyses to assess UTP3 ubiquitination in control and TRIM29-silenced KYSE150 (G) and KYSE510 (H) cells. Representative results of at least three biological replicates are shown. (I) Western blot analyses of TRIM29 and UTP3 in coIP assays performed with control and HCP5-silenced KYSE150 and KYSE510 cells. Representative results of at least three biological replicates are shown. (J and K) Confocal microscopy assessment of PLA spots (red) in the indicated cells. Each spot indicates a single interaction between UTP3 and TRIM29 proteins. Nuclei were stained with DAPI (blue). Scale bars, 10 μm. The data are presented as the means ± SD; two-tailed t test, ∗∗∗p < 0.001, ∗∗p < 0.01; n = 3. (L) Western blot analyses to assess UTP3 ubiquitination in the indicated cells. Representative results of at least three biological replicates are shown.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.